ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.

What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
News
Media Releases
Agendia Announces Publication of Study Validating Use of MammaPrint and BluePrint Molecular Diagnostics using Targeted RNA Next-Generation Sequencing Technology
ย PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ 20 June 2019 โ Agendia, Inc., a world leader in precision oncology, announced today the open access publication of MammaPrint and BluePrint Molecular Diagnostics using Read More
BluePrintยฎ Identifies Genomic Subtypes for African-American Breast Cancer Patients with Low Risk Outcomes
PRESS RELEASE New data presented at ASCO underscores importance of genomic profiling for African-American women with breast cancer whose unique tumor biology can sometimes lead to poorer prognoses ย IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS Read More
Agendia Appoints Two Industry Veterans to Board of Directors
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ 31 May 2019 โ Agendia, Inc., a world leader in precision oncology, announced today the appointment of industry veterans Laurie Heilmann and Franรงois Ferrรฉ, Ph.D. to Read More
Agendia and Imegen Announce an Exclusive Distribution Agreement for MammaPrintยฎ and BluePrintยฎ in Spain and Portugal
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ 21 May 2019 โ Agendia, Inc., a world leader in precision oncology, announced today an agreement with Imegen (Valencia, Spain), for the exclusive distribution of the Read More